Vanguard Capital Wealth Advisors Purchases 4,300 Shares of Bristol-Myers Squibb (NYSE:BMY)

Vanguard Capital Wealth Advisors lifted its position in shares of Bristol-Myers Squibb (NYSE:BMY) by 107.5% in the 4th quarter, Holdings Channel reports. The fund owned 8,300 shares of the biopharmaceutical company’s stock after buying an additional 4,300 shares during the quarter. Vanguard Capital Wealth Advisors’ holdings in Bristol-Myers Squibb were worth $426,000 as of its most recent filing with the SEC.

A number of other institutional investors have also added to or reduced their stakes in the stock. Certuity LLC lifted its holdings in Bristol-Myers Squibb by 55.9% during the 4th quarter. Certuity LLC now owns 40,729 shares of the biopharmaceutical company’s stock worth $2,090,000 after purchasing an additional 14,606 shares in the last quarter. Norden Group LLC raised its holdings in shares of Bristol-Myers Squibb by 7.8% in the 4th quarter. Norden Group LLC now owns 10,633 shares of the biopharmaceutical company’s stock valued at $546,000 after acquiring an additional 773 shares in the last quarter. Penobscot Investment Management Company Inc. raised its holdings in shares of Bristol-Myers Squibb by 3.4% in the 4th quarter. Penobscot Investment Management Company Inc. now owns 18,437 shares of the biopharmaceutical company’s stock valued at $946,000 after acquiring an additional 600 shares in the last quarter. Kestra Private Wealth Services LLC raised its holdings in shares of Bristol-Myers Squibb by 9.4% in the 4th quarter. Kestra Private Wealth Services LLC now owns 152,909 shares of the biopharmaceutical company’s stock valued at $7,846,000 after acquiring an additional 13,098 shares in the last quarter. Finally, Ledyard National Bank raised its holdings in shares of Bristol-Myers Squibb by 1.3% in the 4th quarter. Ledyard National Bank now owns 31,183 shares of the biopharmaceutical company’s stock valued at $1,600,000 after acquiring an additional 393 shares in the last quarter. Hedge funds and other institutional investors own 76.41% of the company’s stock.

Analyst Ratings Changes

Several analysts have weighed in on BMY shares. Societe Generale cut Bristol-Myers Squibb from a “buy” rating to a “hold” rating in a report on Monday, March 11th. Bank of America cut Bristol-Myers Squibb from a “buy” rating to a “neutral” rating and lowered their price target for the company from $68.00 to $60.00 in a report on Wednesday, January 3rd. William Blair reiterated a “market perform” rating on shares of Bristol-Myers Squibb in a research report on Monday, April 1st. Barclays reduced their price objective on Bristol-Myers Squibb from $51.00 to $43.00 and set an “equal weight” rating on the stock in a research report on Friday. Finally, BMO Capital Markets reduced their price objective on Bristol-Myers Squibb from $55.00 to $48.00 and set a “market perform” rating on the stock in a research report on Friday. One research analyst has rated the stock with a sell rating, fifteen have assigned a hold rating and four have assigned a buy rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Hold” and an average target price of $60.00.

Bristol-Myers Squibb Trading Down 1.5 %

Shares of BMY stock traded down $0.68 during trading hours on Tuesday, reaching $43.96. The company’s stock had a trading volume of 17,712,926 shares, compared to its average volume of 15,994,846. The stock has a market capitalization of $89.11 billion, a P/E ratio of -14.38, a P/E/G ratio of 15.47 and a beta of 0.39. Bristol-Myers Squibb has a one year low of $43.93 and a one year high of $69.10. The firm’s fifty day simple moving average is $50.93 and its 200 day simple moving average is $51.02. The company has a current ratio of 1.11, a quick ratio of 0.99 and a debt-to-equity ratio of 2.99.

Bristol-Myers Squibb (NYSE:BMY) last released its earnings results on Thursday, April 25th. The biopharmaceutical company reported ($4.40) EPS for the quarter, beating analysts’ consensus estimates of ($4.53) by $0.13. The company had revenue of $11.87 billion during the quarter, compared to analysts’ expectations of $11.45 billion. Bristol-Myers Squibb had a positive return on equity of 8.83% and a negative net margin of 13.50%. The firm’s revenue for the quarter was up 4.7% compared to the same quarter last year. During the same quarter last year, the business posted $2.05 EPS. Equities research analysts expect that Bristol-Myers Squibb will post 0.58 EPS for the current year.

Bristol-Myers Squibb Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Wednesday, May 1st. Stockholders of record on Friday, April 5th will be paid a $0.60 dividend. This represents a $2.40 dividend on an annualized basis and a dividend yield of 5.46%. The ex-dividend date of this dividend is Thursday, April 4th. Bristol-Myers Squibb’s payout ratio is presently -77.42%.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.